3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Heart Diseases
3
Vascular Diseases
2
Small Cell Lung Carcinoma
2
Cardiovascular Diseases
2
Cardiotoxicity
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Cancer Resectable
1
Ovarian Carcinosarcoma
1
Neoplasms, Second Primary
1
Myelodysplastic Syndromes
1
Metabolic Diseases
1
Leukemia, Myeloid, Acute
1
Leukemia, Monocytic, Acute
1
Immune-related Adverse Event
1
Hematologic Neoplasms
1
Heart Failure
1
Esophageal Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Colorectal Neoplasms
1
Colorectal Cancer Metastatic
1
Carcinoma, Hepatocellular
1
Cancer Therapy-related Cardiovascular Toxicity
1
Breast Neoplasms
1
Advanced Ovarian Cancer
1
Interventions
Cisplatin
7
Etoposide
6
Amifostine
6
Radiotherapy
5
Drug Therapy
5
Cyclophosphamide
5
apatinib
4
Methotrexate
4
Filgrastim
4
Cytarabine
4
sodium thiosulfate
3
Methylprednisolone
3
Carboplatin
3
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Nivolumab
2
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
selinexor
1
sargramostim
1
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Drug-Related Side Effects and Adverse Reactions
×
Antineoplastic Agents
×
Clear all
NCT03882580
2023-04-24
NEOCARDIO
Groupe Hospitalier Pitie-Salpetriere
Unknown
5,000 enrolled